Harmony Biosciences Holdings, Inc. (HRMY) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Plymouth Meeting, PA, アメリカ. 現CEOは Jeffrey Dayno.
HRMY を有する IPO日 2020-08-19, 268 名の正社員, に上場 NASDAQ Global Market, 時価総額 $1.69B.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
